Research study looking for participants with have severe hypertriglyceridemia (elevated fat levels in the blood), which may increase the risk for pancreatitis (inflammation of the pancreas). The study is being carried out to see if a new investigational drug called Evinacumab (human IgG4 monoclonal antibody) decreases the risks of future Recurrent Acute Pancreatitis episodes when given the medication every 4 weeks by infusion for 12 months and follow up visits at 1 and 2 months after your last dose. There will also be 2 follow up telephone calls, so that the total duration you are in the study will be approximately 2 years.